CJC-1295 exists in two commonly discussed forms:
β’ No DAC β shorter half-life, more pulsatile GH signaling
β’ DAC β extended half-life, sustained GH elevation
From a research standpoint, this changes:
β’ Feedback loop dynamics
β’ IGF-1 exposure timing
β’ Recovery vs adaptation emphasis
β Question: If you were designing a research protocol, would you prefer pulsed signaling or continuous elevation β and what outcome would you be optimizing for?